Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany

Autor: Erin Zagadailov, Paul J Bröckelmann, Brian Seal, Timothy M Illidge, Courtney Johnson, Viktor V. Chirikov, Shelby Corman, Cynthia Macahilig, Mehul Dalal
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Oncology
Male
Cancer Research
Immunoconjugates
medicine.medical_treatment
chemotherapy
0302 clinical medicine
Autologous stem-cell transplantation
Recurrence
Germany
Antineoplastic Combined Chemotherapy Protocols
Brentuximab vedotin
Brentuximab Vedotin
Manchester Cancer Research Centre
Hematopoietic Stem Cell Transplantation
Hematology
Hodgkin Disease
humanities
Treatment Outcome
030220 oncology & carcinogenesis
Retreatment
Female
Stem cell
autologous stem cell transplant
medicine.drug
medicine.medical_specialty
Transplantation
Autologous
Relapsed
03 medical and health sciences
brentuximab vedotin
Internal medicine
medicine
Refractory Hodgkin Lymphoma
Humans
In patient
Progression-free survival
Retrospective Studies
Postoperative Care
Chemotherapy
business.industry
ResearchInstitutes_Networks_Beacons/mcrc
Retrospective cohort study
Survival Analysis
United Kingdom
Surgery
body regions
Drug Resistance
Neoplasm
refractory Hodgkin lymphoma
business
progression-free survival
030215 immunology
Zdroj: Zagadailov, E A, Corman, S, Chirikov, V, Johnson, C, Macahilig, C, Seal, B, Dalal, M R, Broeckelmann, P J & Illidge, T 2018, ' Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany ', Leukemia and Lymphoma, vol. 59, no. 6, pp. 1413-1419 . https://doi.org/10.1080/10428194.2017.1382698
Zagadailov, E A, Corman, S, Chirikov, V, Johnson, C, Macahilig, C, Seal, B, Dalal, M R, Broeckelmann, P J & Illidge, T 2018, ' Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany ' Leukemia & lymphoma, vol 59, no. 6, pp. 1413-1419 . DOI: 10.1080/10428194.2017.1382698
Popis: This retrospective study compared effectiveness of (brentuximab vedotin) BV to other chemotherapies in patients with rrHL following an autologous stem cell transplant (ASCT). Data originated from a medical chart review of patients treated in real-world clinical settings at 50 sites in the United Kingdom and Germany. Inverse probability of treatment weights based on propensity scores were used to adjust for differences in baseline characteristics between treatment groups. Among 312 rrHL patients included, 196 received BV and 116 received physicians' choice chemotherapy. Median PFS was significantly longer (27.0 months vs. 13.4 months; p = .0144) and 12-month OS survival greater (78.1% vs. 65.9%; p = .0129) with BV compared to chemotherapy. Documented adverse events included leukopenia (12.8%) and peripheral neuropathy (8.7%) for BV and leukopenia (12.1%), anemia (5.2%) and diarrhea (5.2%) for chemotherapy. In this real-world study, rrHL patients treated for relapse after ASCT with BV had longer median PFS and 12-month OS than patients receiving chemotherapy.
Databáze: OpenAIRE
Externí odkaz: